Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Triple Negative Breast Cancer
Related studies linked through entity extraction aliases.
Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
- Status
- COMPLETED
- Phase
- PHASE2
Brain Monitoring for High Risk of Brain Metastases in Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Emotions Immunology and Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Triple-negative Breast Cancer: a New Perspective on Biomarkers
- Status
- COMPLETED
- Phase
- N/A
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- NA
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2